Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cancer immunotherapies, including immune checkpoint inhibitor (ICI)-based therapies, have revolutionized cancer treatment. However, patient response to ICIs is highly variable, necessitating the development of methods to quickly assess efficacy. In this study, an array of miniaturized bioreactors has been developed to model tumor-immune interactions. This immunotherapeutic high-throughput observation chamber (iHOC) is designed to test the effect of anti-PD-1 antibodies on cancer spheroid (MDA-MB-231, PD-L1+) and T cell (Jurkat) interactions. This system facilitates facile monitoring of T cell inhibition and reactivation using metrics such as tumor infiltration and interleukin-2 (IL-2) secretion. Status of the tumor-immune interactions can be easily captured within the iHOC by measuring IL-2 concentration using a micropillar array where sensitive, quantitative detection is allowed after antibody coating on the surface of array. The iHOC is a platform that can be used to model and monitor cancer-immune interactions in response to immunotherapy in a high-throughput manner.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939119 | PMC |
| http://dx.doi.org/10.1002/smll.202004282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new frontier in oncology: Understanding the landscape of cancer vaccines.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFNon-redundant immune checkpoints direct therapeutic resistance to chemoimmunotherapy in pancreatic ductal adenocarcinoma.
Cancer Immunol Res
September 2025
University of Pennsylvania, Philadelphia, PA, United States.
Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4).
View Article and Find Full Text PDFOncolytic Hydrogel Enhances Immune Checkpoint Blockade by Generating Vaccine, Remodeling Tumor Physical and Metabolic Barriers.
ACS Nano
September 2025
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Although traditional immunogenic cell death (ICD) inducers generate vaccines (ISV) to potentiate antiprogrammed cell death ligand 1 (anti-PDL1) antibodies therapy, their efficacy remains limited. This limitation may be attributed to the physical barrier created by extracellular matrix (ECM) and immunosuppressive metabolic barrier mediated by adenosine. Here, we report an oncolytic polymer (OP), a well-designed ε-polylysine derivative with ICD-inducing capacity, which can simultaneously facilitate the release of endogenous ECM-degrading enzyme, Cathepsin B.
View Article and Find Full Text PDFPsychometric properties of patient-reported outcome measures for symptom assessment in patients with cancer receiving immunotherapy: A systematic review following the COSMIN 2.0 guidelines.
Asia Pac J Oncol Nurs
December 2025
Department of Prevention Management, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Objective: To identify and evaluate the methodological quality and psychometric properties of Patient-reported outcome measures (PROMs) for symptom assessment in patients with cancer undergoing immunotherapy.
Methods: A systematic search was performed in PubMed, Scopus, Cochrane Library, Web of Science, Embase, CINAHL, CNKI, WanFang, Vip, and SinoMed from their inception to February 10, 2025. Eligibility criteria required studies to focus on the development or validation of a PROM for symptom assessment in adult patients with cancer undergoing immunotherapy, and to report on at least one psychometric property.
Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer.
Front Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDF